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Chapter 1. Introduction 
1.1 Chagas disease 
Trypanosoma cruzi, a protozoan parasite, is the causative agent of Chagas Disease, 
a disease of poverty which affects 6-7 million people primarily in Latin America. (1)  It is 
an ancient disease, having been discovered in human mummies dated over 9000 years 
old. (2)    It is considered a neglected tropical disease, however it is now starting to 
become an issue in non-endemic countries such as the US due to migration of people 
from endemic areas of Latin America. (3) 
Chagas disease is endemic to 21 countries in Latin America. It is estimated that 6-7 
million people are currently infected worldwide, including 300,000 people in the United 
States. (2) 70 million people are at risk for infection throughout Latin America. Every 
year, about 30,000 new infections occur and 10,000 people die from Chagas disease 
mainly due to heart complications during the late stage of the disease. (1) The economic 
burden of Chagas disease is over $7 billion annually. (4) 
Chagas Disease was first identified by Dr. Carlos Chagas, a Brazilian physician,  in 
1909. (5)  He named the causative agent, Trypanosoma cruzi, after his mentor Dr. 
Oswaldo Cruz. Dr. Chagas characterized the transmission mode and the entire life cycle 
in vectors and other hosts, a hallmark in the history of parasitology since he determined 
almost every aspect of a new neglected tropical disease on his own. (2) 




Chagas Disease begins when a person is bitten by an infected triatomine bug 
(Figure 1-1A). The insect vector, members of the Reduviidae family Triatominae sub-
family, are popularly referred to as kissing bugs because they often bite the soft facial 
skin. The three main domestic vectors are Rhodnius prolixus, Triatoma dimidiata, and 
Triatoma infestans. (2) 
While the insect takes a bloodmeal, it simultaneously defecates. The insect feces 
contain an infective form of T. cruzi (Figure 1-1B), which can reach underlying cells by 
entering the broken skin when the person rubs or scratches near the bite site. The parasite 
is able to actively invade nearly any type of nucleated cell in the host. (2) 
Once the infection is initiated in the human host, the disease enters the acute 
phase. This normally lasts 4-6 weeks, and is characterized by flu-like symptoms (fever, 
swelling of lymph nodes and tissues, and general malaise), and high blood parasitemia. 
There is often marked inflammation of the area immediately surrounding the bite site, 





Figure 1-1. Overview of Chagas Disease. A. Insect vector for Chagas Disease, T. 
infestans. (6)  B. The causative agent of Chagas Disease, T. cruzi (6)  C. Early clinical 
signs of acute Chagas disease, including Romaña's sign. (6) D. Chest x-ray of normal 





For various reasons, including lack of access to affordable healthcare in the 
countries where Chagas disease is endemic, most cases are not specifically diagnosed, so 
most infected patients are not even aware of their infection. Unfortunately, this early 
acute phase is the only stage where effective treatments are available using the 
trypanocidal drugs Benznidazole and Nifurtimox (8, 9). Most patients resolve the acute 
infection spontaneously even without the use of these trypanocidal drugs, and the number 
of parasites in the blood and tissues significantly declines. Complications during the 
acute phase are usually seen in children where 2-8% of symptomatic child patients may 
die due to cardiac failure (10). 
 For most people at this point, Chagas Disease enters the indeterminate phase. Only 
30% then go on to the chronic phase years (or even decades) later. Often this is the first 
time the patient is diagnosed with Chagas disease even though T. cruzi parasites may 
have persisted for decades (11). Host genetic susceptibility and parasite strain, amongst 
many other possible factors, may play a role in why such a small percentage of 
individuals in the indeterminate phase go on to develop chronic Chagas disease (12).  
Chronic Chagas disease usually manifests as an inflammatory cardiomyopathy, 
which over years leads to enlargement (hypertrophy) of the heart. Figure 1-1D shows an 
x-ray of a normal sized heart, compared to the enlarged Chagasic heart shown in Figure 
1-1E. Chagasic cardiomyopathy is the most common cause of death by heart failure in 
South America. Clinical symptoms include abnormal heart rhythm, heart failure, and 
sudden cardiac arrest (2). Both fibrosis and cell apoptosis as well as amastigotic cyst 




Another possible but less common manifestation of chronic Chagas Disease is 
gastrointestinal megasyndromes, including megacolon, megaesophagus or both, leading 
to digestive malfunction. Amastigotic cysts in the colon or esophagus damage nerves 
thereby decreasing the ability of smooth muscle to dilate and contract. This loss of 
peristalsis leads to the inability to pass stool, leading to pain and malnutrition. A small 
number of people have cardiodigestive Chagas disease, which includes both cardiac as 
well as gastrointestinal symptoms. 
Current prevention efforts have focused on vector control and public awareness 
campaigns (14)  The Southern Cone Initiative, whose goal was to eradicate the insect 
vectors in many of the South American countries and thereby reduce the incidence of 
Chagas Disease (15) have dramatically reduced the incidence of Chagas disease in that 
region. There have also been extensive efforts at vaccine development, however T. cruzi 
has been refractory to vaccine treatment to date (7). Treatment of Chagas Disease is 
primarily accomplished with the drug Benznidazole, which is mostly effective in the 
acute phase of the disease (16). There are current drug trials of extended treatment with 
Benznidazole in chronic Chagas, and results to date have been somewhat promising (17). 
However, Benznidazole has very severe and unpleasant side effects, and administration is 
very complicated, so development of alternative treatments is very important. (7, 18) 
Epidemiological data on Chagas Disease is very inconsistent. Recently, the World 
Health organization collected health statistics on Chagas Disease from all Latin American 
countries. (1)  In many of these countries, health care is financially out of reach for many 
people, so many of the people most at risk for being infected rarely go to doctors for 
diagnosis and treatment, and therefore data cannot be consistently collected. The data for 
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these countries was estimated based on sampling, although the methods for this varied 
widely in quality and depth between countries. 
1.2 T. cruzi biology/lifecycle 
T. cruzi has a complex lifecycle, as do many protozoan parasites, which alternates 
between mammalian hosts and insect vector as shown in Figure 1-2A. There are three 
distinctive forms of T. cruzi during the lifecycle: epimastigote, trypomastigote and 
amastigote. The parasite takes the epimastigote form in the midgut of the insect vector 
where it replicates. The parasites then transit to the hindgut where they differentiate into 
the infective metacyclic trypomastigotes. When the insect vector takes a bloodmeal, it 
simultaneously defecates. The insect feces contain the metacyclic trypomastigotes which 
can reach underlying cells by entering the broken skin when the person rubs or scratches 





Figure 1-2. The T. cruzi parasite across the lifecycle. A. T. cruzi has a complex 
lifecycle including two distinct forms in the insect vector and two in the host. (20) B. The 
epimastigote is the replicative form of the parasite in the insect vector. The 
trypomastigote is the infective form of the parasite. The amastigote is the replicative, 
intracellular form of the parasite in host cells. (21) C. Trypomastigote (infective) form of 




Once the parasite is inside the mammalian host, the trypomastigotes can invade 
virtually any nucleated cell. Once inside the cell, the parasite transforms into the 
amastigote form within 24 hours, where it replicates for approximately four days until it 
transforms back into the trypomastigote form and bursts out of the cell to infect 
neighboring cells. If the infected host is again bitten by an insect vector, circulating 
trypomastigotes are ingested with the bloodmeal, which transform into epimastigotes in 
the midgut, completing the cycle (19). 
The three forms of T. cruzi (epimastigote, trypomastigote and amastigote, Figure 
1-2B) are most easily distinguished by the location of nucleus relative to the kinetoplast. 
The kinetoplast is a mitochondria-like organelle located anterior to the nucleus in the 
epimastigote. In the trypomastigote the nucleus is centrally positioned and kinetoplast is 
located towards the posterior end of the parasite. In the amastigote, the kinetoplast is 
located anterior to the nucleus, and the flagellum is very short. Cartoons of the two forms 
of T. cruzi used in this study are shown in Figure 1-2 C and D.  
The kinetoplast, in addition to producing the energy needed for the operation of 
the flagellum in the same manner as a mitochondrion, contains “mini-circles” of DNA 
used for splicing the polycistronic transcripts produced by the parasite (23,24),  and also 
contains guide RNAs used to edit transcripts post-transcriptionally. (25) 
T. cruzi is unusual among parasites in that it can invade virtually any nucleated 
cell. (26)  It has a wide variety of surface molecules that it uses for attachment and 
invasion, allowing it to be successful at invading this wide variety of cells. Figure 1-3 









Once the parasite is near a host cell, it can use one or more of these molecules, 
either secreting them, or “wounding” the cell membrane and bringing all of the related  
host cell mechanisms in to play to be exploited by the parasite (28, 19). 
Figure 1-4 shows our current understanding of the infection timeline. Using one 
or more of the molecules identified in Figure 1-3, the parasite invades the cell within 15 
minutes of attachment, and is enclosed by a portion of the host cell membrane, becoming 
the parasitophorous vacuole (29). This vacuole is often (but not exclusively) made out of 
recruited lysosomes from inside the host cell, and in fact retain the markers associated 
with lysosomes, such as LAMP1 (30). The lysosomes cover the parasite during its initial 
entry into the host, and stay in place for approximately 8 hours while the parasite begins 
its transformation into the intracellular, replicative amastigote form. The parasite 
eventually produces an acidic environment inside the parasitophorous vacuole, as well as 
a pore-forming protein TcTox, which helps to disrupt the membrane, and allows the 
parasite to escape into the cytosol. (26, 31) 
The parasite completes its transformation by 24 hrs and starts dividing. By around 
96 hpi, the parasite begins the transformation back to the trypomastigote form. The 





Figure 1-4. Infection dynamics of T. cruzi. Schematic representation of samples 
collected from the infection of human foreskin fibroblasts (HFF) with T. cruzi Sylvio 
strain. The expected progression of the T. cruzi infection is shown. Briefly, the parasite 
invades the cell within 15 minutes of attachment, and is enclosed by a portion of the host 
cell membrane (parasitophorous vacuole). By 4 hours post-infection (hpi), the parasite 
begins to transform from infective trypomastigote to the intracellular amastigote; it exits 
from the parasitophorous vacuole at around 8 hpi. The parasite completes its 
transformation by 24 hrs and starts dividing. By around 96 hpi, the parasite begins the 
transformation back to the trypomastigote form. The trypomastigotes then escape the cell 




In addition to the infective trypomastigote form of the parasite, amastigotes which 
enter the host tissues when an infected cell bursts are also capable of invading other host 
cells. In some cases, the amastigotes transform back into the invasive trypomastigote 
form, but some strains, particularly those in DTU TcI (32, 33), have extracellular 
amastigotes that are capable of invading both professional and non-professional 
phagocytic cells by hijacking host cell actin pathways. (34, 35).  
1.3 T. cruzi population structure 
T. cruzi reproduces clonally, but there appears to be at least one historical 
hybridization event leading to strains with different haplotypes. The population structure 
is described by assigning the various strains of T. cruzi into six discrete typing units 
(DTUs): TcI to TcVI (36, 37, 38)  based on molecular markers. While there is some 
debate as to the number of hybridization events that have occurred to produce the 
heterozygous strains in DTUs V and VI, there is broad agreement that DTUs I and II are 
pure ancient lineages. (38) 
 A phylogenetic analysis of 32 unlinked genetic loci in representative samples 
from all six DTUs have provided strong evidence for only a single hybridization event, 




Figure 1-5. Population structure of T. cruzi. 32 loci in 48 strains were sequenced. 
Phylogenetic analysis with bootstrap support produced this tree 75% of the time, with 




 It appears that the historical hybridization event occurred between DTU II and 
DTU III, with one haplotype in each of the hybrid strains clustering with the hybrid 
DTUs TcV and TcVI.  
There appear to be biochemical and clinical differences between the various 
strains of T. cruzi parasites. A study in rats looked at heart tissue after infection with four 
different strains of T. cruzi including a DTU TcI strain (Col1.7G2) and a DTU TcII strain 
(Y). The DTU TcI strain showed considerably lower cardiomyopathy, inflammation 
(heart and digestive organs), and cardiac denervation in these rats (40). In a study 
involving dogs infected with either DTU TcI strain (Col) or DTU TcII strain(Y), the TcII 
strain showed considerably more cardiac fibrosis than TcI (41). In a study in mice using 
T. cruzi isolates circulating in Argentina, the isolates typed as DTU TcI showed more 
damage to skeletal muscle compared to the DTU TcII organisms, which showed more 
inflammation in heart tissue. (42)   
In humans, there seems to be a higher rate in gastrointestinal symptoms associated 
with DTU TcII parasites (43) and altered ECG (44) compared to DTU TcI.  
 In addition to biological differences between parasite strains, there is different 
geographical distribution of the strains as shown in Figure 1-6. In the Northern portion of 
South America, extending through Central America, strains in DTU TcI predominate. In 
the Southern cone area of South America, strains in DTU TcII as well as hybrid strains in 
DTU TcVI predominate. There is a section in the middle, particularly in Peru and the 









Robust epidemiological studies tying disease symptoms to parasite strain are 
lacking, although a recent study suggested that the rate of Chagas cardiomyopathy may 
be lower in countries with DTU I as the dominant strain compared to DTU II dominant 
countries (1). In addition, different vector species and transmission cycles have been 
documented for DTU I and DTU II (45). 
1.4 Reference genomes 
There are several reference genomes published for T. cruzi. The first T. cruzi 
genome was published in 2005 for the CL Brener strain (46), which was selected as the 
reference strain for the T. cruzi Genome Project (47). CL Brener, a hybrid strain assigned 
to DTU VI, has two heterozygous haplotypes, with approximately 50% of the genome 
representing repeat sequences. There are numerous multigene families, with 46 having 
more than 20 copies, and the largest two having over 1300 copies. These multigene 
families are thought to play a role in virulence (48). 
  The CL Brener genome was further finished and assigned to 41 pairs of 
chromosomes which range from approximately 78kb to 2.4Mb (49). 21133 genes were 
identified in the final chromosome assembly. 
The second sequenced T. cruzi genome was for the Sylvio strain (50), the strain 
used in this study. The Sylvio sequencing study reported that the protein-coding regions 
of the two sequenced strains Sylvio strain (DTU TcI) and CL Brener (DTU TcVI) are 97-
98% identical even though their geographical distribution  is quite different. 
Recently two additional genomes were published for the DTU TcI strain Dm28c 
(51) and the related bat-specific Marinkellei strain (DTU TcBat) (52). The Dm28c 
genome was found to be highly similar to the Sylvio genome (also a DTU TcI strain) 
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with a reported 98% nucleotide sequence identity and 6,094 proteins with best hits with 
Sylvio. The matches for CL Brener are 90% sequence identity and 5,267 protein best hits. 
The Marinkellei genome was compared to the Sylvio and CL Brener genomes. There was 
a difference in copy number in multigene families between the strains, with the Sylvio 
genome generally having more families than Marinkellei with the exception of the 
dispersed gene family. This family in Sylvio was also contracted compared to CL Brener. 
Nucleotide identity in orthologous gene pairs was 93% with all compared genomes (6283 
orthologous genes in Sylvio, 5441 genes in CL Brener Esmeraldo-like haplotype and 
5617 genes in CL Brener Non-Esmeraldo-like haplotype) 
1.5 Review of current state of research and gaps 
The majority of existing studies that look at infected host cells report either host or 
parasite individually, primarily because most studies to date have been done using 
microarrays.  
A microarray study was done looking at the transcriptome of HeLa cells infected 
with the Tulahuen (TcVI) (53). This study looked at a single timepoint, 3 days post-
infection. The effects of control cells were removed, and differential expression was 
reported for significantly up- and down-regulated genes. Their primary finding was that 
cell proliferation genes were being regulated to suppress host cell proliferation. 
Another study looked at three different host cell types- fibroblasts, endothelial cells 
and smooth muscle cells, using microarrays (54). The cells were infected with Y strain 
and the data was collected 24 hours post-infection. The study detected a prominent type I 
interferon response as well as cellular repair pathways, and a reduction in mitotic cell 
cycle and cell division. 
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Rat myoblasts were interrogated using microarrays and infecting with four different 
strains of T. cruzi- Brazil (TcI), Y (TcII), CL (TcVI) and Tulahuen (TcVI) at 72 hours 
post-infection (55). They found that Tulahuen caused the most differential expression of 
these strains (17% of genes significantly DE), and Y strain the least (6% of genes). While 
the affected genes were not identical across strains, they found that similar pathways 
were altered by all four strains. 
Mouse cardiomyocytes were infected with Brazil (TcI) strain and interrogated with 
microarrays 48 hours post-infection (56). Differentially expressed genes were primarily 
in the immune response, extracellular matrix and cell adhesion pathways, consistent with 
the kinds of pathogenesis seen in cardiac Chagas. 
 A study using Tulahuen infected human cardiomyocytes was performed to 
interrogate the early (0-120 minutes post-infection) timepoints using a microarray (57). A 
fibrogenic response was observed in these cells, consistent with the cardiac pathology 
seen in cardiac Chagas Disease. 
The earliest full transcriptome using RNASeq was performed on Trypanosoma 
brucei (58). This work was used to further confirm the genome assembly, and provided 
evidence for bi-directional transcription from initiation sites, and also transcription from 
internal sites, not just Pol II initiation sites. 
A microarray study of gene transcription in all four stages of the T. cruzi Brazil 
strain parasite (59) showed that transcript abundance for different genes was regulated 
across the parasite lifecycle. They also found that different members of multi-gene 
families seemed to predominate at different lifecycle stages.  
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 Several proteomic studies of parasites have been performed, including one 
looking at all four stages of the parasite as the genome was published. In this study (21), 
they confirmed the proteins associated with many hypothetical proteins, and also 
proposed that the insect stages of the parasite use distinctly different energy sources, with 
histidine predominating in the insect forms and fatty acids used by intracellular 
amastigotes.  
In another proteomic study, the trypomastigote versus amastigote forms of DTU 
TcI patient isolates were compared (60), showing that proteins associated with oxidative 
stress, especially tryparedoxin peroxidase, were increased, which could be associated 
with intracellular survival and a defense against immune response. 
Finally, a meta-analysis of T. cruzi infection experiments was done (61) finding 
that there is little commonality between infection assays across the literature making it 
difficult to compare results between studies, and that the majority of experiments used 
either Tulahuen or Y strain, and very few using DTU TcI, as we do in our study. 
The first RNASeq study of T. cruzi was our previous work with Y strain (DTU 
TcII) (62). This work extends this initial study by comparing the results to a DTU TcI 
strain, Sylvio. 
1.6 Summary of dissertation work 
The aim of this study was to conduct gene expression profiling of DTU TcI and 
DTU TcII T. cruzi  infecting human host cells (Human foreskin fibroblasts) using RNA-
Seq. We investigated the global differences at the transcription level as a proxy for 
translation to identify biological pathways and cellular functions being performed by the 
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host and parasite as the infection progressed. By following both host and parasite 
transcriptomes over time, we hoped to better understand the host-pathogen interaction. 
An improved understanding of the molecular basis for this disease will assist in 
developing preventive vaccines and/or targeted drugs with less toxicity. Further, the 
differential expression profile for the two strains of parasite will potentially give us 
insight into the different clinical presentation given by TcI and TcII parasite strains. 
Chapter 2 provides a description of the materials and methods used to produce the 
data for this study. 
Chapter 3 discusses the results of the infection experiments including the RNA 
isolation, sequencing, mapping to the genome and counting each transcript. 
Chapter 4 discusses the differential expression and GOSeq analysis for the human 
data. 
Chapter 5 discusses the differential expression and GOSeq analysis for the 
parasite data. 
Chapter 6 contains concluding remarks and proposes future directions for this 
work. 
This work has been submitted for publication. 
Contributions to this work: Genevieve Houston-Ludlam (GHL) and Najib El-Sayed 
(NES) conceived the project and designed experiments; GHL performed experiments; 
GHL, Ashton Trey Belew (ATB), Hector Corrada Bravo (HCB) and NES analyzed data;  
GHL and NES wrote the paper submitted based on this work. All the sequencing was 
21 
 
performed at the University of Maryland Institute for Bioscience and Biotechnology 




Chapter 2. Materials and Methods 
2.1 Infection experiments 
Low-passage primary human foreskin fibroblasts (HFF) BJ strain (ATCC CRL-
2522) were propagated in Dulbecco's Modified Eagle Medium (DMEM, Gibco) with 
10% fetal heat-inactivated bovine serum (FBS, Gemini Bioproducts), 1x MEM Non-
essential Amino Acids (Cellgro) and 100 units Penicillin/100 µg Streptomycin/0.25 µg 
Amphotericin per mL (DMEM-10% FBS) and incubated at 37°C in 5% CO2. Following 
expansion, 2.5x105 cells were seeded into 6-well plates in DMEM-10% FBS for 48 
hours. Identical wells were prepared for microscopy with glass microscope coverslips for 
parasite burden computation. Two biological replicates, each originating from separate 
freeze dates after expansion from the original ATCC culture, were performed. 
Parasites were maintained as pure cultures of epimastigotes in LIT media 
supplemented with 10% HI-FBS at 27ºC. Epimastigotes were transformed to metacyclic 
trypomastigotes by leaving the parasites in the spent media for 14 days. The combined 
epimastigote/metacyclic trypomastigotes were placed on Vero Cells for 24 hours, then 
the media was replaced with 10% Horse Serum for 24 hours. The cells were then 
incubated in DMEM-2% FBS. When TCTs erupted, they were placed on a new Vero cell 
culture, and DMEM supplemented with 10% horse serum was used as growth media until 
there were no more visible epimastigotes in the flask or on the hemocytometer during cell 
counts. Further passages of TCTs were then grown in DMEM supplemented with 2% HI-
FBS. Stabilates were made of the pure TCT cultures in 50% HI-FBS, 40% DMEM and 
10% DMSO and then 1 mL vials were cryopreserved in liquid nitrogen.as the starting 
point for all infections. 
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Stabilates of T. cruzi strains Sylvio and Y were propagated in monolayers of Vero 
cells in DMEM (Cellgro) with 2% heat-inactivated FBS (Gemini Bioproducts), 1x MEM 
Non-Essential Amino Acids (Cellgro) and 100 units Penicillin/100 µg Streptomycin per 
mL (DMEM-2% FBS). Tissue culture trypomastigotes (TCTs) were harvested from the 
supernatant, centrifuged and resuspended in DMEM-2% FBS. Parasites (3.0 x 107 
parasites per well, 100:1 infection MOI) were incubated with HFF cells for 2 hours at 
37°C at 5% CO2 to allow invasion. The remaining extracellular parasites were aspirated, 
each well was washed 5 times with PBS, fresh DMEM-2% FBS medium was added, and 
cultures were incubated for the indicated times. Timepoints were taken at 4, 12, 20, 24, 
30, 48, 72 and 96 hours post-infection (hpi). Each biological replicate originated from a 
different stabilate of Sylvio or Y strain after expansion from the original culture.  




Table 2-1. List of cells used in this study. The source for each cell line is provided 
Materials Catalog numbers Sources 
Vero Cells  CCL-81 ATCC 
Human Foreskin Fibroblasts- BJ line CRL-2522 ATCC 
T. cruzi Sylvio (DTU I) 50800 ATCC 







2.2 RNA sequencing 
Media was aspirated from wells and 1 mL Trizol® reagent (Life Technologies) 
was applied to the cell culture. The Trizol® mixture was then collected and immediately 
placed in a -80 °C freezer until total RNA could be isolated according to the Trizol® 
protocol. Residual DNA was degraded using DNase and the remaining RNA was purified 
with a Qiagen RNeasy mini kit. RNA quantification and quality were assessed with an 
Agilent 2100 Bioanalyzer. PolyA+ cDNA libraries were prepared with the Illumina 
TruSeq Sample Preparation kit (San Diego, CA, USA) using the Illumina indexes for 
multiple samples per lane. Libraries were checked for quality and quantity using the 
Agilent Bioanalyzer 2100 and qPCR (KAPA Biosystems), then sequenced on an Illumina 
Hi-Seq 1500. 
Wells with coverslips were fixed with 4% paraformaldehyde for ten minutes. The 
coverslips were washed five times with PBS, mounted onto microscope slides with 
ProLong Gold antifade reagent along with DAPI stain (Life Technologies) and allowed to 
set overnight at room temperature in the dark. Parasites were counted at 100x oil 
immersion on a Zeiss AxioObserver Microscope. One hundred cells on each coverslip 
were counted, with three coverslips per timepoint. Percent infected HFF cells and parasite 
burden per infected cell were computed. 
2.3 RNA-Seq data processing and mapping 
Paired-end reads (100 bp) were demultiplexed then trimmed for residual adapter 
sequences using Trimmomatic (63). Trimmed reads were checked for per-base quality 
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using FastQC (64) and sequences with poor quality at the ends were further trimmed with 
Trimmomatic. Reads were aligned with Tophat (version 2.0.10) (Kim et al., 2013) to the 
appropriate reference genome (hg19 for human, TriTrypDB version 4.1 for CL Brener 
Esmeraldo-like haplotype (proxy genome for Y-strain parasite) (46) or TriTrypDB 
version 6.0 for Sylvio parasite (50). Two mismatches per read were allowed and reads 
were allowed to map only to a single locus. The number of reads mapping to each gene 
feature in the corresponding annotation files was determined using HTSeq (66).  
2.4 Transcriptome analysis 
Data for human and parasite samples collected in this study and data from our 
previous work were checked for consistency between replicates using a variety of global 
inter-sample correlation analyses including Pearson correlation, median pairwise 
correlation (MPC), box plots, principal component analysis (PCA) and Euclidean 
distance-based hierarchical clustering. A standard method for identifying outliers was 
applied to the data samples (67). The median pairwise correlation (MPC) for the first 
quartile across samples was computed (Q1), as was the inter-quartile range (IQR). 
Briefly, any sample whose MPC was less than Q1-1.5(IQR) was removed as an outlier. 
Two samples were removed from the human data based on this criterion. No parasite 
samples were removed. 
Weakly expressed genes, defined as having less than 1 read per million in ‘n’ of 
the samples, where ‘n’ is the size of the smallest group of replicates (68) (here n=10 and 
6 for the T. cruzi and human samples, respectively) were removed from subsequent 
analyses. Data were quantile normalized and log2 transformed (69, 70). The list of 
differentially expressed (DE) genes was determined using voom (71) to account for the 
27 
 
mean-variance relationship, then the data were fitted to a linear model, which included 
batch to account for experimental batch effects in the data (72), using limma (73,74). 
Benjamini-Hochberg multiple testing correction was applied at an FDR cutoff <0.05 to 
determine significance (75). 
 Version 8.0 genome fasta files for T. cruzi Sylvio strain and T. cruzi CL Brener 
strain (Esmeraldo-like haplotype) were evaluated to identify uniquely mapping orthologs. 
The FASTA program ggsearch36 (76), which does a global alignment, was used with 
default parameters (E-value <= 0.001, score > 0). Reciprocal best hits were then further 
refined by removing genes in the four largest multi-gene families (Mucin associated 
surface protein, trans-sialidase, retrotransposon hot-spot and dispersed gene family 
protein), thereby avoiding the problems introduced by assembly of highly similar and 
repetitive genes. Altogether there were 4,659 unique orthologs, of which 3,279 (70%) 
were annotated as hypothetical proteins. This set of genes is referred to as the “core” set 
of parasite genes. 
 The GO Term Finder (77) was applied to the human and parasite data using the 
server at go.princeton.edu. For the human data, Ensembl IDs were converted to HUGO 
Gene Nomenclature Committee Database (HGNC) IDs with the BioMart ID Conversion 
tool, then GO Term Finder was applied with the “GOA + HGNC Xrefs- H. sapiens 
(human)” annotation. The human data was also interrogated with g:Profiler (78) to 
simultaneously identify GO, KEGG and Reactome term enrichment. For T. cruzi, the GO 
terms were extracted from the Version 9.0 TriTrypDB text file into a standard gene 




Chapter 3. Infection Experiments 
In this study, we investigated whether we could detect differences in the global 
transcriptomes of two T. cruzi  strains Sylvio (DTU I) and Y (DTU II) and their host cell 
given the distinct clinical and biochemical profiles suggested by previous reports 
(75,36,76,50,77,37). Using RNA-Seq, we simultaneously interrogated the transcriptomes 
of both the host and the parasite over the course of the intracellular infection. Three 
independent Sylvio infections were carried out in HFF cells. We performed a single 
limited experiment with Y strain-infected HFF cells during replicate 1 of the Sylvio 
experiments to check for consistency across experimental dates and to allow us to 
evaluate batch effects.  
 
Three replicate experiments were performed as shown in Table 3-1. Each 
biological replicate originated from a different stabilate of Sylvio or Y strain. To avoid 
the impact of infective amastigotes in the media (35), the number of amastigotes was 
counted by hemocytometer along with trypomastigotes prior to the infection, with a 






Table 3-1. Description of three replicate experiments.  Dates of the respective 
experiments, stabilates used and percentage of amastigotes in the media used to initiate 
infection are reported. 
Replicate 
Date of 
Experiment HFF Stabilate 
Sylvio Stabilate Y Stabilate 
% Amas 
1 6/16/2013 3/31/2103 2/26/2013 5/24/2012 3.20% 
2 7/7/2013 3/15/2013 2/26/2013 NA 4.09% 





T. cruzi strains Sylvio and Y were propagated in monolayers of Vero cells in 
DMEM (Cellgro) with 2% heat-inactivated Fetal Bovine Serum (Gemini Bioproducts), 
1x MEM Non-Essential Amino Acids (Cellgro) and 100 units Penicillin/100 µg 
Streptomycin per mL (DMEM-2% FBS). Tissue culture trypomastigotes (TCTs) were 
harvested from the supernatant, centrifuged and resuspended in DMEM-2% FBS. 
Parasites (3.0 x 107 parasites per well, 100:1 infection MOI) were incubated with HFF 
cells for 2 hours at 37°C at 5% CO2 to allow invasion. The remaining extracellular 
parasites were aspirated, each well was washed 5 times with PBS, fresh DMEM-2% FBS 
medium was added, and cultures were incubated for the indicated times. For each 
replicate, timepoints were taken at 4, 12, 20, 24, 30, 48, 72 and 96 hours post-infection. 
An aliquot of the trypomastigotes used to begin the infection was also collected. RNA 
from each timepoint was harvested from infected cells and matched uninfected control 
cells using Trizol® reagent, and the parallel wells with microscope cover slips were 
fixed, stained with DAPI and mounted on microscope slides. 
 
3.1 Microscopy 
The stained coverslips from each timepoint were counted using a Zeiss 
Observer.Z1 Fluorescent Microscope. Pictures were captured using the attached Zeiss 
Axiocam MRm Rev. 3 camera, and analyzed and stored using AxioVision Software 
V4.8.2.0. 
Each timepoint had three replicate coverslips for infected cells. One coverslip from 
control cells was also observed to ensure that there was no readily observable difference 
in the growth characteristics between control and infected host cells. 100 cells per 
coverslip were counted to compute percent infected cells as well as parasites per infected 
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cell. Figure 3-1 shows an example of a snapshot of cells at each timepoint at 400x 
magnification. 
Counting was done at 1000x with oil to clearly visualize the nucleus and 
kinetoplast of each parasite. Figure 3-2 shows the results of the counting performed at 
1000x magnification. Figure 3-2A shows an example of an intracellular amastigote 
compared to a host cell nucleus at 1000x with oil. Both nucleus and kinetoplast were 
visualized for each parasite while counting to avoid counting cell debris. This count is 
therefore considered a conservative estimate. Figure 3-2B shows the percentage of 
infected cells across replicates. This was computed as the number of cells with at least 
one parasite divided by the total number of cells for that timepoint. Figure 3-2C shows 
the number of parasites per infected cell (“parasite burden”) across replicates. This was 





Figure 3-1. Microscope snapshots of infected HFFs across time.  HFF cells infected 
with T. cruzi Sylvio strain were stained with DAPI and observed at 400x magnification 
on a Zeiss Observer.Z1 Fluorescent Microscope using UV light. The increase in the 





Figure 3-2. Results of microscopy for Sylvio and Y experiments. Coverslips with 
infected cells were counted at 1000x magnification with oil on a Zeiss Observer.Z1 
Fluorescent Microscope using UV light. One hundred cells on each of three independent 
cover slips per experimental timepoint were counted. A. A host cell nucleus with a 
parasite. Both the parasite nucleus (round) as well as the kinetoplast (linear) are clearly 
visible. B. Percent infected cells. This was computed as the number of cells with at least 
one parasite divided by the total number of cells for that timepoint. C. Number of 
parasites per infected cell. This was computed as the number of parasites divided by the 
number of infected cells for that timepoint. Both the nucleus and the kinetoplast had to be 
seen for that parasite to be counted to ensure that cellular debris was not inadvertently 





As can be seen readily in Figure 3-2B, the third replicate, performed 8/11/13, had 
remarkably different infection dynamics compared to the other two replicates. This, 
combined with the smaller parasite burden as seen in the later timepoints in Figure 3-2C 
and the lower amount of RNA seen after RNA isolation caused us to drop this third 
replicate at this point and not continue with it into sequencing. 
The replicate infections with T. cruzi Sylvio strain behaved consistently with an 
approximate parasite burden of two parasites per infected cell at 4 hpi and about 65% of 
the host cells infected. Parasite division was observed beginning at 24 hpi. Both Sylvio 
and Y strains displayed similar infection dynamics and behaved consistently with the 
existing Y strain dataset (62). Most importantly, both Sylvio and Y strains followed the 
expected time course parameters of an experimental T. cruzi infection as previously 
described (81).  
 
3.2 RNA isolation and quality evaluation 
 
Total RNA from infected and uninfected human cells and parasite TCTs was 
isolated for each of the biological replicates using the Trizol® protocol and purified with 
a Qiagen RNeasy mini kit. After isolation, the isolated total RNA was submitted for 
analysis by an Agilent Bioanalyzer 2100. Figure 3-3 is a sample Bioanalyzer report for 
total RNA from various types of samples. Figure 3-3A is parasite only, Figure 3-3B is 
human only (control), Figure 3-3C is an infected host sample (both signals). The spikes 






Figure 3-3. Analysis of total RNA quality and quantity. A. Example Bioanalyzer run 
for trypomastigote stage T. cruzi parasites. The three major rRNA peaks associated with 
the T. cruzi parasite are seen. B. Example Bioanalyzer run for uninfected HFF cells. The 
two major human rRNA peaks are seen. C. Example Bioanalyzer run for T. cruzi Sylvio-
infected HFF cells. The peaks for both human and parasite are seen, with the large 




labeled. All of the spikes are clearly present for both human and parasite in Figure 3-3C, 
the infected human cells. 
3.3 Library preparation and sequencing 
Poly(A)+ enriched cDNA libraries were generated using the Illumina HiSeq 
Library Preparation Protocol version 2. cDNA quality was assessed using the Agilent 
Bioanalyzer 2100. Figure 3-4 is a sample Bioanalyzer report for cDNA. The majority of 
cDNAs fall around 300bp, the ideal size for the Illumina sequencer.  
Quantity was determined by KAPA Biosystems qPCR. The libraries were 
sequenced using the Illumina HiSeq 1500 platform to produce paired-end, 100bp reads. A 
total of ~1.1 billion reads were produced across 16 samples, with overall 94% mapping to 








Figure 3-4. Analysis of quality of cDNA library. The majority of cDNAs fall around 






Table 3-2. Sample information. Metadata, total sequenced reads, and mapped reads; 
these are defined by number and percentage aligned to human, Sylvio, and the 





After sequencing, the reads were demultiplexed into individual samples using the 
standard Illumina sequencing index that was incorporated into the samples during library 
preparation. The sequences were then trimmed for residual adapter sequences using 
Trimmomatic (63). Trimmed reads were checked for per-base quality using FastQC (64) 
and sequences with poor quality at the ends (quality score error bar dropping below 20) 
were further trimmed with Trimmomatic. An example per-base quality report is shown in 
Figure 3-5. 
Reads were aligned with Tophat (version 2.0.10) (65) to the appropriate reference 
genome (hg19 for human, TriTrypDB version 4.1 for CL Brener Esmeraldo-like 
haplotype (proxy genome for Y-strain parasite) (46) or TriTrypDB version 6.0 for Sylvio 
parasite (50). Two mismatches per read were allowed and reads were allowed to map 
only to a single locus. 
Because RNA-seq reads could be mapped unambiguously to the host and parasite 
reference genomes, we were able to track the respective fractions of RNA for each 
species in each sample. Our analysis revealed a proportion of 1.7% of the total mRNA 
population attributable to the parasite early in the infection (4 hpi). The parasite’s 
contribution increased to 4.2% at 24 hpi, consistent with the expected doubling beginning 








Figure 3-5. Example fastQC per-base quality report. Each bar represents the range of 
quality scores for the given positional range of nucleotides, beginning with the first 
nucleotide in each adapter-trimmed read and proceeding to the end of the read. The 
quality score lower error bar was used to determine if this sample was of sufficient 
quality to proceed. No further trimming was required for this (or any) sample as all 






3.4 Gene counts 
The number of reads mapping to each gene feature in the corresponding annotation 
files was determined using HTSeq (66). The output of this tool was a count table with the 
number of reads mapping to each gene in the reference annotation. These “count tables” 
formed the basis for all further analysis.  
Count table data for human and parasite samples collected in this study was 
combined with data from our previous work. These combined data were checked for 
consistency between replicates using a variety of global inter- and intra-sample 
correlation analyses, as described for the human data in Chapter 4 and for the parasite in 




Chapter 4. Human Data 
4.1 Library size 
To visualize the depth of sequencing of the various samples, we plotted the raw 
library size of all samples as shown in Figure 4-1. All further analysis is performed on 
library-size normalized data to account for these differences in sequencing depth. 
An inherent assumption for quantile normalization is that the count data has  the 
same underlying distribution. To evaluate the data against this assumption, a density plot 
of library size-normalized gene counts (82) for each sample was generated as shown in 
Figure 4-2. This density analysis showed the estimated underlying distribution of 
abundance of reads mapping to each gene feature. The near superimposed curves showed 
that the distribution of counts was consistent within human samples. Human gene 
expression is frequently regulated at the transcriptional initiation level, with many genes 
turned off under different conditions (83), and this is reflected in the spike at zero count. 
This spike does not affect the downstream data analysis because all low-count genes are 
dropped prior to data normalization (68). Other than this spike, the remainder of the 
expression pattern  has the same underlying distribution, so our assumption for quantile 





Figure 4-1. Barplot of raw library sizes for all human samples. Each bar represents 
the number of reads for a single sample in the combined dataset. Color represents a 
experimental batch, from experiments performed starting on the same day. Batches G and 




Figure 4-2. Density plot of all human samples. Each curve represents an individual 
sample in the combined dataset. Ideally, all curves would be superimposed, and the data 
would show  the same underlying distribution. Counts (expression level) are library size-





A different view of the same data, focusing on the mean count, is shown in Figure 
4-3. The library size normalized mean count and range did not differ substantially 
between samples. 
4.2 Identification of outlier samples 
A Pearson correlation was computed for all samples against all samples in the 
combined dataset. A heatmap showing the resulting correlation matrix is shown in Figure 
4-4. 
There was generally very good inter-sample correlation across the entire dataset. 
The dendrogram highlights that there were clusters of correlation, which roughly 
correspond to samples taken at particular timepoints. Early timepoints (4-12 hpi) tended 
to cluster together, as did middle (24 hpi) and late (48-72 hpi) timepoints. The two 
datapoints at the left/bottom of the chart (red) had the lowest correlation, and were 
dropped after subsequent analysis. 
A standard method for identifying outliers was applied to the data samples (67). 
The median pairwise correlation (MPC) for the first quartile across samples was 
computed (Q1), as was the inter-quartile range (IQR). Briefly, any sample whose MPC 






Figure 4-3. Boxplot of library size normalized counts by sample. Each box represents 
an individual sample in the combined dataset. Ideally, all boxes would have exactly the 
same mean (horizontal line) and range. Counts (expression level) are library size-






Figure 4-4. Pearson correlation heatmap. This heatmap visualizes the Pearson 
correlation matrix for each sample compared to every other sample in the combined 
dataset. Color at the intersection of each sample pair represents the Pearson correlation 




removed as an outlier. A scatterplot of median pairwise correlation for each sample is 
shown in Figure 4-5. 
Two samples (Y72_G and S72_H) were removed from the human data based on 
this criterion.  
4.3 Pairwise comparisons 
 
To evaluate variance between pairs of samples, we produced a series of pairwise 
MA plots. Examples of these plots are shown in Figure 4-6.  
These plots compare the ratio of expression levels for each gene (log count per 
million) between two samples versus the average expression. Essentially, the further the 
ratio is from the center line, the more variance there is in that sample. Figure 4-6A is an 
example of two samples with low variance per gene. Figure 4-6B is an example of two 
samples with considerable variance. There were a few pairs of samples that showed a 
large amount of dispersion, particularly early timepoints compared to late ones, however 






Figure 4-5. Scatterplot of median pairwise Pearson correlation. Each point represents 
the median pairwise correlation for that sample with all other samples in the dataset. The 
horizontal line is the interquartile range cutoff, computed as median pairwise correlation 





Figure 4-6. Sample MA plots for evaluating pairwise data dispersion between 
samples. A. Comparison of a control and infected human sample at 4hpi in the same 




4.4 Principal component analysis 
A principal component analysis was performed on low-count filtered, quantile 
normalized per-gene counts from both species, incorporating data produced in this study 
with the Y strain data from our previous study. Principal Component analysis extracts 
important information from a table of data, combines it into a set of “principal 
components” which represent patterns of similarity and variability in the data, and allow 
that similarity/variability to be visualized (84). This allowed us to evaluate any potential 
batch effects introduced by the different labs and the different experimental timeframes. 
Batch effects are confounding variables, such as date of experiment, lab or technician, 
which cause variation in the data completely separate from the underlying biology (72). 
These batch effects can confound the results of biological studies and should be identified 
and corrected. (85) 
Low count, or weakly expressed genes, are defined as having less than 1 read per 
million in ‘n’ of the samples, where ‘n’ is the size of the smallest group of replicates 
(Anders et al., 2013) (here n= 3 for human samples). These low-count reads were 
removed from subsequent analyses. Of 21036 genes with Hugo annotations (protein 
coding genes) in the count tables, 13063 (62%) passed the low-count filter and continued 
on to principal component analysis. 
The low count filtered data were quantile normalized and log2 transformed (69).  
The singular value decomposition of the normalized and transformed combined 
dataset was computed. The resulting covariance matrix of the genes forms the basis of the 
principal component scores (86). To evaluate which genes had the biggest impact on 
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principal component 1, which explains the largest amount (35%) of the variance, sorted 
loadings were plotted across all genes as shown in Figure 4-7. 
 Of 2206 low-count filtered genes,  13063 (17%) had a loading greater than 0.01 
(knee of the curve).   The variance matrix was then evaluated to determine the variance 
of each principal component and how that variance correlates with experimental batch 
and experimental condition (Control or infected combined with hpi). The resulting table 






Figure 4-7. Loading analysis of uncorrected PC1. Sorted loadings were plotted across 






Table 4-1. Variance for each principal component without batch correction. For 
each principal component, the proportion of total variance in the dataset explained by that 
PC, and the contribution of condition (control or infected and timepoint) and 







1 35.44 88.55 45.59 
2 27.65 68.34 90.49 
3 11.4 83.88 11.26 
4 5.02 81.96 16.9 
5 3.24 34.77 72.87 
6 2.3 15.9 64.48 
7 1.88 63.05 31.15 
8 1.51 48.76 31.49 
9 1.24 27.58 19.19 
10 1.03 26.3 59.34 
 
 We then plotted the Principal component scores for PC1 against PC2 for each 





Figure 4-8. Uncorrected principal component analysis for human data. Principal 
component score for PC1 is plotted against the principal component score for PC2 for 
each sample. Color represents time hpi for infected samples. Control samples are shown 
in increasingly dark grayscale for increasing time hpi. Shape corresponds to experimental 
batch as shown in the key. Batches G and H were produced as part of this research, and 





In the uncorrected PCA, principal component 1 is associated with time hpi, with 
early timepoints clustering toward the left and later timepoints clustering on the right. 
Principal component 2 appears highly associated with experimental batch, with samples 
produced in our previous work on the bottom and samples produced as part of this work 
on the top. This is evidence of batch effect in this data, so we included batch as a 
covariant in the linear model incorporated into the limma program (87) used to evaluate 
differential expression. 
 One of the underlying assumptions in these linear models is the independence of 
mean and variance in gene counts. However, in this type of count-based data, variance is 
often larger at lower mean counts. To include batch in the linear model, and to also 
correct for the mean-variance relationship, we used the voom package (71) to weight 
each gene. The mean-variance trend computed by voom as part of data weighting is 
shown in Figure 4-9. 
After the data was weighted and batch was included in the linear model, the 
principal component analysis was repeated. The variance matrix was recomputed, and a 
new singular value decomposition was produced to determine the new variance of each 





Figure 4-9. Mean-variance trend in uncorrected combined Human data. The 
trendline is produced by the voom package as part of computing weights to correct for 






Table 4-2. Variance for each principal component with batch included in limma 
model. For each principal component, the proportion of total variance in the dataset 
explained by that PC, and the contribution of condition (control or infected and 
timepoint) for that PC are reported. The influence of batch has been removed by 





1 44.3 58.33 
2 20.49 82.89 
3 9.38 85.7 
4 3.68 62.37 
5 2.67 27.55 
6 2.56 43.27 
7 1.86 52.42 
8 1.57 52.32 
9 1.4 68.41 






We then plotted the new Principal component scores for PC1 against PC2 for 
each sample as shown in Figure 4-10. 
Principal component 1 (PC1) showed a progression of time post-infection, with 
early timepoints clustering on one end and later timepoints on the other. Control 
(uninfected) samples clearly separated from infected samples along PC2, with the 
distance between control and infected cells growing larger as the infection progressed. 
Datapoints from this study, experimental batches G and H, grouped tightly with the data 
produced previously despite the experiments being run in two different collaborating 
laboratories more than a year apart. This analysis also convinced us that including batch 
in the limma model was sufficient to account for batch effects, and that further batch 






Figure 4-10. Principal component analysis, batch in limma model. Principal 
Component score for PC1 is plotted against the Principal component score for PC2 for 
each sample. Color represents time hpi for infected samples as shown in key. Control 
samples are shown in increasingly dark grayscale for increasing time hpi. Shape 
corresponds to experimental batch as shown in the key. Batches G and H were produced 




4.5 Differential expression analysis  
There were 13892 a total of expressed (non-zero) genes in the human dataset. 
Differential expression for the human data was computed for each timepoint subtracting 
the effects of the control cells because, as seen in the principal component analysis, HFF 
cells change over time in culture. Differential expression was computed on these control-
corrected gene counts. 
The limma topTable function (73) was utilized to provide summary statistics on a 
per-gene basis at each timepoint for differential expression analysis. Log2(Fold Change) 
was returned from the linear model to represent difference in expression between infected 
and control HFFs. The primary method of determining significance for each gene is the 
moderated t-statistic. The moderated t-statistic uses increased degrees of freedom in 
connection with underlying smoothing across genes. Both p-values as well as adjusted p-
values (using Benjamini-Hochberg multiple-testing adjustment) are provided. Finally, the 
B statistic is provided which represents the log odds that the gene is differentially 
expressed. This value usually orders genes the same way as p-value. 
The q-value, which is an adjusted p-value using prior probabilities of each gene 
not being differentially expressed (Bayesian posterior p-value), was also computed (88).  
The number of Differentially Expressed genes for the human data is shown in 
Table 4-3. 
A graphical representation of the similarities and differences in the host response 
to infection with the two different strains of the T. cruzi parasite is shown in the form of a 
scatter plot of log2 fold change to visualize the shared signature (Figure 4-11).  
62 
 
Overall, a striking similarity was seen between the host response to Sylvio and Y 
strains of T. cruzi when comparing genes that are significantly DE in both infections, and 
had a fold change greater than 2 (89). At 24 hpi, HFFs infected with Sylvio or Y shared a 
common set of 113 genes that were significantly upregulated (Figure 4-11A, quadrant I). 
There were no significantly DE genes co-downregulated or upregulated exclusively in 
Sylvio or Y infections at 24 hpi. There was a marked increase in the number of shared 
genes significantly DE between 24 hpi and 72 hpi. By 72 hpi (Figure 4-11B), the number 
of genes that were significantly DE in HFFs infected with either Sylvio or Y in the same 
direction increased to 358. Of these, 291 (81%) were commonly upregulated and 67 
(19%) were downregulated (Figure 4-11B, quadrants I and III respectively). An 
examination of these shared genes revealed that of the 113 genes significantly DE at 24 
hpi, 102 (90.3%) were still significantly DE at 72 hpi. We conclude that most of the early 
response signature remained over the course of the infection with an additional 





Table 4-3. Summary of differential expression analysis for human data. Summary of 
differentially expressed genes with their direction (up- or downregulated) at various fold 
change cutoffs at various timepoints. To be considered differentially expressed, a gene 
















FC| > 1 (red) 
Significant DE 
Genes 316 7690 289   176   113   
Both Upregulated 
(Q1) 260 3512 243 84.1% 130 73.9% 113 100.0% 
Y Up, Sylvio 
Down (Q2)     0 0.0% 0 0.0% 0 0.0% 
Both 
Downregulated 
(Q3) 56 4178 46 15.9% 46 26.1% 0 0.0% 
Sylvio Up, Y 
Down (Q4)     0 0.0% 0 0.0% 0 0.0% 
                  
72 hpi                 
Significant DE 
Genes 6526 4301 2227   1828   399   
Both Upregulated 
(Q1) 2972 1930 944 42.4% 653 35.7% 291 72.9% 
Y Up, Sylvio 
Down (Q2)     207 9.3% 184 10.1% 23 5.8% 
Both 
Downregulated 
(Q3) 3554 2371 891 40.0% 824 45.1% 67 16.8% 
Sylvio Up, Y 
Down (Q4)     185 8.3% 167 9.1% 18 4.5% 
  no FC cutoff |log2 FC| > 1  




hpi 72 hpi Merge 
Both Upregulated 
(Q1) 243 944 206 84.8% 113 291 102 90.3% 
Both 
Downregulated 







Figure 4-11. Comparative analysis of the host transcriptome response to infection 
with Sylvio versus Y strain. Scatterplot of log2 fold change in expression of human 
genes in HFF cells infected with Sylvio (x-axis) versus Y (y-axis) at 24 hpi (A) and 72 
hpi (B). Genes that were not significantly differentially expressed are shown as gray dots. 
Pink dots represent significantly DE genes in infections with both strains but had log2 FC 
in one or both strains that was below our cutoff value of 1. Red dots depict genes that 
were significantly DE and had absolute value of log2 FC>1 in both strains. The numbers 
in each quadrant correspond to the total number of significantly DE genes that met the 
log2 FC cutoff of 1 (red) or were significantly DE but did not meet the FC cutoff (pink). 
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4.6  Gene ontology analysis 
 To evaluate the biological activity being performed by the host cell for this shared 
signature, the GO Term Finder (77) was applied to the human data using the server at 
go.princeton.edu. Ensembl IDs were converted to HUGO Gene Nomenclature Committee 
Database (HGNC) IDs with the BioMart ID Conversion tool, then GO Term Finder was 
applied with the “GOA + HGNC Xrefs- H. sapiens (human)” annotation. The human data 
was also interrogated with g:Profiler (78) to simultaneously identify GO, KEGG and 
Reactome term enrichment (90, 91).  
As shown in Table 4-4, GO analysis of the co-upregulated genes shows a general 
innate immune response at 24 hpi, with Type I interferon response being the most 
vigorous (three out of the top ten GO terms).  
A similar enrichment was observed at 72 hpi as shown in Table 4-5. 
 
A KEGG analysis showed an upregulation in sterol biosynthesis pathway at 72 
hpi. A GO analysis of the significantly DE co-downregulated genes (Figure 4-11B, 
Quadrant III) showed a downregulation of the cell cycle. All of these observations were 






Table 4-4. Top ten GO terms for host genes upregulated in infections with both 
Sylvio and Y strains at 24 hpi. A list of all significantly upregulated genes in both 
Sylvio and Y strains which also had a log2 Fold Change > 1 were provided to the GO 
Term Finder









GO:0051607 defense response to virus 9.79E-53 39 111 
GO:0009615 response to virus 3.38E-52 41 111 
GO:0045087 innate immune response 2.44E-51 56 111 
GO:0006955 immune response 1.73E-48 62 111 
GO:0006952 defense response 4.88E-48 61 111 
GO:0098542 
defense response to 
other organism 7.27E-47 41 111 
GO:0060337 
type I interferon 
signaling pathway 2.95E-43 28 111 
GO:0071357 
cellular response to type 
I interferon 2.95E-43 28 111 
GO:0034340 
response to type I 
interferon 4.44E-43 28 111 







Table 4-5. Top twenty GO terms for host genes upregulated in infections with both 
Sylvio and Y strains at 72 hpi. A list of all significantly upregulated genes in both 
Sylvio and Y strains which also had a log2 Fold Change > 1 were provided to the GO 
Term Finder 









GO:0002376 immune system process 2.74E-59 121 281 
GO:0006955 immune response 3.25E-58 104 281 
GO:0045087 innate immune response 6.82E-56 86 281 
GO:0006952 defense response 3.28E-55 100 281 
GO:0043207 
response to external biotic 
stimulus 7.33E-44 63 281 
GO:0051707 
response to other 
organism 7.33E-44 63 281 
GO:0009607 
response to biotic 
stimulus 1.53E-42 63 281 
GO:0034097 response to cytokine 2.32E-42 64 281 
GO:0009615 response to virus 7.10E-41 47 281 
GO:0051607 defense response to virus 5.88E-40 43 281 
GO:0006950 response to stress 7.03E-40 126 281 
GO:0009605 
response to external 
stimulus 1.95E-38 93 281 
GO:0010033 
response to organic 
substance 1.05E-37 100 281 
GO:0098542 
defense response to other 
organism 6.00E-37 48 281 
GO:0060337 
type I interferon signaling 
pathway 6.77E-37 32 281 
GO:0071357 
cellular response to type I 
interferon 6.77E-37 32 281 
GO:0034340 
response to type I 
interferon 8.57E-37 32 281 
GO:0071345 
cellular response to 
cytokine stimulus 4.36E-36 56 281 
GO:0051704 multi-organism process 5.68E-36 85 281 
GO:0019221 
cytokine-mediated 






We infer from our observations that the host cell transcriptomes when infected 
with either Sylvio or Y strain of T. cruzi are remarkably consistent.The signature 
behavior of the host when infected with T. cruzi includes upregulation of the innate 
immune response, specifically the Type I interferon response, an upregulation in the 
sterol biosynthesis pathway, and a downregulation in the mitotic cell cycle.  All of these 
are consistent with our previous work, and are also consistent with observed behavior in 
these and previous published experiments.There were a few detectable differences in the 
host cell response to the two strains which did not appear until 72 hpi. A total of 41 genes 
were upregulated in only one strain and downregulated in the other. Of those, 23 genes 
were upregulated in Y strain infections and downregulated in Sylvio infections (Figure 
4-11B, quadrant II) and do not reflect any discernible signature. The remaining 18 genes 
were upregulated in Sylvio infections and downregulated in Y strain infections (Figure 
4-11B, quadrant IV). While we did not identify any GO categories that were significantly 
overrepresented among those genes, we note that the genes encoding IL-8 and IL-32 
behave very differently in host cells infected by the two different T. cruzi strains. IL-8 is 
a chemokine which attracts monocytes to an area of injury or infection. IL-32 causes the 
production of pro-inflammatory cytokines and chemokines, including IL-8. One can 
speculate that the upregulation of these two cytokines in Sylvio infected cells could offer 
a partial explanation of the difference in the overall clinical picture between the 
infections with the two strains by attracting immune cells to respond to host cells infected 
with Sylvio. This biological relevance of this observation can only be ascertained by 
testing a greater number of replicates in vitro, testing additional parasite strains as well as 
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establishing that similar expression patterns can be observed in patients infected with the 
two strains. 
We compared the top differentially expressed genes in Sylvio to the list of top 
differentially expressed genes in a study of Tulahuen strain (TcVI) T. cruzi infecting 
HeLa cells (53). The results of shared DE genes are shown in Table 4-6. These shared 
genes show the same interferon-induced picture as the Sylvio and Y strain, and also show 





Table 4-6. Top ten shared genes upregulated in HeLa cells infected with Tulahuen 
strain of T. cruzi.   Gene ID in the original study, gene function, Log2 Fold change in 
Tulahuen, Ensembl ID for the gene in this study and Log2 Fold Change in Sylvio 
infected HFF cells. 
Gene Description log2FC Ensembl ID log2FC 
IL8 interleukin 8 2.9 ENSG00000
169429 
4.8 
IL6 interleukin 6 (interferon, beta 2)  2.9 ENSG00000
136244 
2.4 
HERC5 hect domain and RLD 5  2.6 ENSG00000
138646 
5.9 
IFI44 interferon-induced protein 44  2.5 ENSG00000
137965 
3.6 
IFIT2 interferon-induced protein with 











IFIT3 interferon-induced protein with 











IFIT1 interferon-induced protein with 












Chapter 5. Parasite Data 
5.1 Parasite orthologs 
Because the annotation and closure of the T. cruzi genomes are considerably less 
mature than the human genome, and the gene naming scheme between CL Brener 
Esmeraldo-Like (proxy for Y strain) and Sylvio strain was completely different, we 
generated a set of orthologs to allow mapping of genes between the two strains. Version 
8.0 genome fasta files for T. cruzi Sylvio strain and T. cruzi CL Brener strain (Esmeraldo-
like haplotype) were used to generate these orthologs. The FASTA program ggsearch36 
(76), which does a global alignment, was used with default parameters (E-value <= 
0.001, score > 0). Reciprocal best hits provided 6273 orthologs from Sylvio to 
Esmeraldo-like, and 6346 orthologs in the opposite direction. This is comparable to the 
6094 bidirectional best hits BBH reported between T. cruzi Dm28c and Sylvio strains, 
and 5267 BBH between Dm28c and CL Brener. (51)  They are also comparable to the 
number of reported orthologs between T. cruzi marinkellei and Sylvio strain (6283), 
Esmeraldo-like haplotype of CL Brener (5441) and non-Esmeraldo-like haplotype (5617) 
(52). 
The orthologs lists were then further refined by removing genes in the four largest 
multi-gene families (MASP, trans-sialidase, retrotransposon hot-spot and dispersed gene 
family protein), thereby avoiding the problems introduced by assembly of highly similar 
and repetitive genes.  
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Altogether there were 4,659 unique orthologs, of which 3,279 (70%) were 
annotated as hypothetical proteins. This set of genes is referred to as the “core” set of 
parasite genes. This list allowed us to unambiguously compare expression levels for 
orthologous genes in both strains despite the different naming conventions for genes in 
Sylvio and Y strains. The process and gene counts during the various steps of developing 







Figure 5-1. Process of developing core set of orthologs. Each set of ovals represents a 
step in the process of developing the core ortholog set. “Total annotation features” are the 
protein coding genes in the respective .gff file from TriTrypDB. “Hits from fasta” are the 
genes that had any number of orthologs between the two strains using ggsearch36. 
“RBH” are the genes that had mutual best hit pairs. “Multifamily Removed” was the 
process of removing the top four multigene families by name. The last step finds unique 
reciprocal best hits in both strains. Only the top four hits were returned, the E score had 
to be less than 0.001, and the match score had to be greater than 0 for ggsearch36 to 




5.2 Library size 
To visualize the depth of sequencing of the various samples, we plotted the raw 
library size of all samples as shown in Figure 5-2. All further analysis is performed on 
library-size normalized data to account for differences in sequencing depth. 
For the parasite data, batches G and H were combined into one batch because the 
second replicate of Sylvio data being in its own batch confounded batch with strain. The 
combined batch G was produced as part of this research. Batches A-E were produced in 
our prior work. 
5.3 Count data statistics across samples 
To verify that the data has the same underlying distribution in the parasite data, a 
density plot of library size-normalized gene counts for each parasite sample was 
generated as shown in Figure 5-3. 
Figure 5-3B highlights different aspects of gene expression regulation in human 
and parasite genes. Human gene expression is frequently regulated at the transcriptional 
initiation level, with many genes turned off under different conditions leading to the spike 
at zero count. The T. cruzi parasite (like other trypanasomatids) transcribes the majority 
of its genes in polycistronic units (92) and fine-tunes steady-state mRNA levels post-




Figure 5-2. Barplot of raw library sizes for all parasite samples. Each bar represents 
the number of reads for a single sample in the combined dataset. Color represents a 





Figure 5-3. Density plot of all parasite samples and comparison with human density. 
A. Each curve represents an individual sample in the combined dataset. Ideally, all curves 
would be superimposed, and the data would show  the same underlying distribution. 
Counts (expression level) are library size-normalized to address the differences in 




A different view of the same data, focusing on the mean count, is shown in Figure 
5-4. 
The library size normalized mean count did not differ substantially between 
samples. There was a difference between the Sylvio samples and the Y strain samples 
(including the ones produced in this study) at the high expression end (log2 expression > 
9). We evaluated the genes that were missing in those samples. The four genes that were 
very highly expressed in Y strain but not in Sylvio are shown in Table 5-1. The functions 
of these four genes did not indicate any functional or biochemical pattern, so no further 






Figure 5-4. Boxplot of library size normalized counts by sample. Each box represents 
an individual sample in the combined dataset. Ideally, all boxes would have exactly the 
same mean (horizontal line) and range. Counts (expression level) are library size-







Table 5-1. Genes highly expressed in Y strain but not Sylvio.     
Y Gene ID Sylvio Gene 
ID 































5.4 Identification of outlier samples 
A Pearson correlation was computed for all samples against all samples in the 
combined parasite dataset. A heatmap showing the resulting correlation matrix is shown 
in Figure 5-5. 
There was generally very good inter-sample correlation across the entire dataset 
for Y strain samples, including the two Y strain datapoints produced in this research. The 
dendrogram clearly separates Sylvio samples from Y strain samples. Within strain, 
separation was between early timepoints (4 hpi-24 hpi) and late timepoints (24 hpi-72 
hpi).  
A standard method for identifying outliers was applied to the data samples (67). 
The median pairwise correlation (MPC) for the first quartile across samples was 
computed (Q1), as was the inter-quartile range (IQR). Briefly, any sample whose MPC 
was less than Q1-1.5(IQR) was removed as an outlier. A scatterplot of median pairwise 
correlation for each sample is shown in Figure 5-6. 
The Y strain parasite data showed good correlation between biological replicates. 
With the full set of all possible orthologs (Figure 5-6A), the Sylvio strain data showed 
considerably lower correlation with the Y strain data than when limited to the uniquely 





Figure 5-5. Pearson correlation heatmap. This heatmap visualizes the Pearson 
correlation matrix for each sample compared to every other sample in the combined 
dataset. Color at the intersection of each sample pair represents the Pearson correlation 





Figure 5-6. Scatterplots of median pairwise Pearson correlation. Each point 
represents the median pairwise correlation for that sample with all other samples in the 
dataset. The horizontal line is the interquartile range cutoff, computed as median pairwise 
correlation (MPC) for the first quartile across samples – 1.5 times the inter-quartile range 
(IQR). A. Median Pairwise Correlation of all genes with any ortholog. B. Median 




5.5 Principal component analysis 
A principal component analysis was performed on quantile normalized per-gene 
counts from both strains incorporating data produced in this study with the Y strain data 
from our previous study. This allowed us to evaluate any potential batch effects 
introduced by the different labs and the different experimental timeframes. 
Because transcription of genes in trypanosomatids is not turned off at the 
individual gene level, no parasite genes were removed from processing by the low count 
filter. Data were quantile normalized and log2 transformed (69).  
As described for the human data, the singular value decomposition of the 
normalized and transformed combined dataset was computed. The resulting covariance 
matrix of the genes forms the basis of the principal component scores (86). To evaluate 
which genes had the biggest impact on principal component 1, which explains the largest 
amount (40%) of the variance, sorted loadings were plotted across all genes as shown in 
Figure 5-7. 
Of 318 low-count filtered genes,  4653 (7%) had a loading greater than 




Figure 5-7. Loading analysis of uncorrected PC1. Sorted loadings were plotted across 





 The variance matrix was then evaluated to determine the variance of each 
principal component and how that variance correlates with batch and experimental 
condition (strain combined with hpi). The resulting table is shown in Table 5-2. 
We then plotted the Principal component scores for PC1 against PC2 for each 





Table 5-2. Variance for each principal component without batch correction. For 
each principal component, the proportion of total variance in the dataset explained by that 








1 39.52 99.61 66.6 
2 29.49 98.86 22.57 
3 4.98 93.56 7.48 
4 4.21 97.04 22.25 
5 3.92 17.63 79.52 
6 2.39 50.89 13.74 
7 2.17 43.09 24.8 
8 2.05 7.2 4.32 
9 1.42 15.81 29.14 







Figure 5-8. Uncorrected principal component analysis for parasite data. Principal 
component score for PC1 is plotted against the principal component score for PC2 for 
each sample. Color represents time hpi for infected samples. Shape corresponds to batch 
as shown in the key. Batch G was produced as part of this research, and batches A-E 





In the uncorrected PCA, principal component 1 is associated with strain, and 
principal component 2 is associated with time hpi, with early timepoints clustering at the 
bottom and later timepoints clustering at the top. The two Y strain datapoints produced in 
this work cluster nicely with their timepoint-matched datapoints from our previous work. 
This is evidence that batch effect is not a major contributor to variance in the parasite 
data. 
  To correct for the mean-variance relationship, we used the voom package (71) to 
weight each gene. The mean-variance trend computed by voom as part of data weighting 
is shown in Figure 5-9. 
 After the data was weighted and batch was included in the linear model, the 
principal component analysis was repeated. The variance matrix was recomputed, and a 
new singular value decomposition was produced to determine the new variance of each 





Figure 5-9. Mean-variance trend in uncorrected combined human data. The 
trendline is produced by the voom package as part of computing weights to correct for 




Table 5-3. Variance for each principal component with batch included as a 
covariate in limma model. For each principal component, the proportion of total 
variance in the dataset explained by that PC, and the contribution of condition (control or 
infected and timepoint) for that PC are reported. The influence of batch has been 





1 49.44 99.96 
2 26.99 99.29 
3 8.25 99.19 
4 5.3 97.72 
5 1.85 28.79 
6 1.63 94.69 
7 1.16 8.57 
8 0.97 41.28 
9 0.81 33.72 





 We then plotted the new Principal component scores for PC1 against PC2 for 
each sample as shown in Figure 5-10. 
The parasite data showed a clear separation along PC1 between T. cruzi Sylvio 
and Y strains, with the 4 hour timepoint for Sylvio strain relatively close to the 
corresponding Y strain datapoints and the distance increasing as the infection progressed. 
PC2 reflected the progression of time post-infection. The early timepoints (4-6 hpi) 
clustered together, when the parasite is still expected to be in the parasitophorous vacuole 
and beginning its transition from the infective trypomastigote into the intracellular 
replicative form. The datapoints from 12 hpi, when the parasite would have left the 
parasitophorous vacuole, are clustered between the early and late timepoints. Finally, the 
data from the later timepoints, 24 to 72 hpi, when the parasite would be dividing among 
other things, clustered together tightly within strain. Similarly to the human data, the Y 
strain datapoints produced in this study grouped with the corresponding Y strain 
timepoints from the existing data.  
The separation of Y and Sylvio strain was more than expected considering that 
the parasite PCA analysis was limited to a core orthologous gene set defined in our study. 
This reduced dataset excluded many of the multi-gene family members which include 
many of the virulence factors associated with attachment and invasion and have generally 





Figure 5-10. Principal component analysis, batch included as a covariate in limma 
model. Principal Component score for PC1 is plotted against the Principal component 
score for PC2 for each sample. Color represents time hpi for infected samples as shown 
in key. Shape corresponds to batch as shown in the key. Batch G was produced as part of 









5.6 Differential expression analysis 
We examined the parasite transcriptome during the infection of a human host cell 
by generating DE profiles for T. cruzi Sylvio and comparing them to the DE lists 
generated for T. cruzi Y infection in our previous study  (62). All T. cruzi Sylvio-infected 
samples (no outliers) and the full set of genes in the Version 8.0 TriTrypDB Sylvio 
annotation were used for differential expression analysis. The analysis performed was 
identical to the one carried out on the human data as described in Chapter 4, with some 
additional limitations inherent to the parasite genome(s). While the human genome is 
finished and well annotated, the parasite reference genomes used in this study are not 
fully assembled because of their high repeat content and the multigene families. The CL 
Brener strain of T. cruzi, the original sequenced genome (46) represents the most 
‘finished’ genome including chromosome-assigned scaffolds (93), whereas the Sylvio 
genome assembly consists of 19,000 contigs (50). In addition, a large proportion (~60%) 
of the gene products in T. cruzi are annotated as ‘hypothetical’ and the gene ontology 
labels and KEGG pathway assignments are sparse.  
Similar to our observations in the host cell response to the two strains, a striking 
similarity was seen between the response of Sylvio and Y strains of T. cruzi when the 
significantly DE core genes were compared.  
A summary of the number of Differentially Expressed genes for the parasite data 
is shown in Table 5-4. 
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A graphical representation of the similarities and differences between the two 
strains as the parasite transitions from the 4 to 24 hpi is shown in the form of a scatter 
plot (Figure 5-11).  
There was a common set of 119 core genes that were significantly DE at greater 
than 2 fold. Of these, 88 were commonly upregulated (Figure 5-11, quadrant I), and 31 
were commonly downregulated (Figure 5-11, quadrant III) in both strains. Between 24 
and 72 hpi, only 4 shared genes were significantly DE at greater than 2 FC (Table 5-4). 
The substantially larger number of genes differentially expressed between 4 and 24 hpi 
than between 24 and 72 hpi are consistent with our current understanding of the biology 
of the parasite during infection and our previous observations in T. cruzi Y strain . After 
invading the host cell, T. cruzi begins its transformation from the invasive trypomastigote 
form into the intracellular, replicative amastigote form. Once it completes this 
transformation within the first 24 hpi, it continues dividing approximately every 12 hours 





Table 5-4. Summary of differential expression analysis of parasite data. Summary of 
differentially expressed core genes with their direction (up- or downregulated) at various 
fold change cutoffs for early versus late timepoints. To be considered differentially 
expressed, a gene must have a q-value < 0.05. 



















Genes 3470 5403             
Core Significant 
DE Genes 1769 2747 1280   1159   121   
Both 
Upregulated 
(Q1)     540 42.2% 452 39.0% 88 72.7% 
Y Up, Sylvio 
Down (Q2)     42 3.3% 41 3.5% 1 0.8% 
Both 
Downregulated 
(Q3)     649 50.7% 618 53.3% 31 25.6% 
Sylvio Up, Y 
Down (Q4)     49 3.8% 48 4.1% 1 0.8% 
72 v 24                 
Significant DE 
Genes 308 139             
Core Significant 
DE Genes 145 71 20   16   4   
Upregulated 63 32 8 40.0% 7 43.8% 1 25.0% 






Figure 5-11. Comparative analysis of T. cruzi parasite Sylvio versus Y strain 
transcriptome response.  Scatterplot of log2 fold change in expression of a subset of 
orthologous T. cruzi parasite genes in Sylvio (x-axis) versus Y strain (y-axis) at 24 hpi 





5.7 Gene ontology analysis 
 The GO Term Finder (77) was applied to the parasite data using the server at 
go.princeton.edu. The GO terms for T. cruzi were extracted from the Version 9.0 
TriTrypDB text file into a standard gene association file (GAF format) and provided in 
the advanced input options. 
We examined the shared parasite signature for Gene Ontology enrichment in the 
subset of genes significantly DE between 4 and 24 hpi. Analysis of all co-upregulated 
genes revealed an enrichment of lipid and sterol biosynthesis pathways, consistent with 
our previous observations in T. cruzi Y strain (62). We also noted an enrichment of the 
one-carbon metabolism process (GO:0006730). This process produces the precursors for 
the production of trypanothione, a key metabolite responsible for addressing oxidative 
stress in trypanosomes, as trypanothione reductase mutants have been shown to be 
avirulent (94).  
The one carbon/redox biochemical pathway has a large number of differentially 
expressed genes in the Sylvio and Y strain parasite. These genes are overlayed onto a 
pathway diagram in Figure 5-12. Taken together, the genes that are overexpressed 
generally appear to be increasing production of precursors to glutathione (GSH), and 
generally those that are underexpressed appear to be rescuing components of glutathione 
from catabolism. Glutathione is the precursor to trypanothione, a central molecule in the 
antioxidant defense system of the parasite (96). In fact, the drug currently in use to treat 
Chagas disease, Benznidazole, appears to act by covalently binding to trypanothione, 





Figure 5-12. Differentially expressed genes in T. cruzi parasite and their role in 
redox chemistry.  One carbon metabolism (95) leading into redox chemistry (96) is 
shown. Genes in red represent genes which are differentially expressed in both strains of 
parasite. Genes in purple met the fold-change criterion in one strain of parasite but not the 
other. Genes in green are differentially expressed in only one strain of parasite. Blue 
shows the current understanding of the actions of drugs that are used or studied in Chagas 




Table 5-5. Enzymes involved in one carbon metabolism. The most common 
abbreviation, the enzyme name, the Enzyme Commission number, and whether this gene 
is differentially expressed in the parasite transcriptome. 
Abbrevi-
ation 




APx ascorbate peroxidase  EC 1.11.1.11 Yes 
BHMT2 homocysteine S-methyltransferase  EC 2.1.1.10 Yes 
CSE γ-cystathionase EC 4.4.1.1 No 
CβS cystathione β-synthase EC 4.2.1.22 No 
DHAR 
dehydroascorbate reductase (aka 
glutathione dehydrogenase) EC 1.8.5.1 No 
GCAT glycine C-acetyltransferase  EC 2.3.1.29 Yes 
GCL γ-glutamylcysteine synthetase EC 6.3.2.2 No 
GLDH glutamate dehydrogenase  EC 1.4.1.2 Yes 
GPx Glutathione peroxidase  EC 1.11.1.9 No 
GR glutathione reductase  EC 1.8.1.7 No 
GSS GSH synthetase EC 6.3.2.3 No 
MAT methionine adenosyltransferase  EC 2.5.1.6 No 
MS methionine synthase EC 2.1.1.13 No 
MTAP methylthioadenosine phosphorylase  EC 2.4.2.28 Yes 
PDXK  pyridoxal kinase  EC 2.7.1.35 Yes 
R-MT transmethylation reactions   
RR Ribonucleotide Reductase  EC 1.17.4.1 No 
SAHH S-adenosylhomocysteine hydrolase EC 3.3.1.1 Yes 
TryR trypanothione reductase  EC 1.8.1.12 Yes 
TryS trypanothione synthase  EC 6.3.1.9 No 












GSH Glutathione (reduced) 
GSSG Glutathione disulfide (oxidized) 
Nt ribonucleotides 
R-OOH  hydroperoxides 
T(SH)2 Trypanothione disulfide (reduced) 






Targeting the one carbon/trypanothione metabolic pathway appears to be a very 
active area of current drug research in Chagas Disease. Currently, there are active lines of 
research looking at: Primaquine, an antimalarial drug which inhibits peroxidal kinase 
(PDXK), thereby reducing availability of vitamin B6, a central enzymatic cofactor in 
many metabolic reactions (98, 99); Quinoxalone derivatives, which target trypanothione 
reductase (TryR) thereby reducing the pool of trypanothione (100); Use of Vitamin B12 
(cofactor for methionine synthase (MS)), alone or in combination with trypanocidal drugs 
(101); and Tryparedoxin (Txn) as a drug target (102) 
 
Significantly DE co-downregulated genes showed no significant GO enrichment. 
Only two significant DE genes meeting the fold change cutoff were unique to one strain 
or the other. One was a hypothetical protein (TcCLB.507143.60/TCSYLVIO_002455) 
upregulated ~3-fold in Y but downregulated ~2.8-fold in Sylvio. The other was an amino 
acid permease (TcCLB.511325.50/TCSYLVIO_010159) upregulated ~2.8-fold in Sylvio 





Chapter 6. Concluding Remarks/Future Prospects 
Our analysis found a remarkable consistency between both parasite and host 
responses to infections with both strains of parasite. Our findings are consistent with 
previously published work, and also published reports looking at these individual 
pathway responses. This work, combined with our previous work provides a deep dive 
into the transcription behavior of both host and T. cruzi parasite, and a comparison in the 
host-pathogen interaction between infections with two different strains of T. cruzi. In 
addition, we have made the full set of host and parasite transcription data available in 
public repositories, unlike previous transcriptome studies which only reported on a subset 
of genes.Finally, we identified a potentially significant difference in host response 
regarding IL-8, which could potentially lead to an explanation for the difference in 
clinical outcomes in chronic Chagas Disease when infected with DTU TcI vs. DTU TcII 
strains. 
The similarity in host response to the two strains of parasite could be explained by 
the fact that the in vitro system used in this study necessarily removes all influences of 
the immune system, which would be seen in an in vivo experiment, and this interaction 
may show a marked difference in either host or parasite response to infection. An in vivo 
experiment using PBMC or similar types of circulating cells in infected humans in the 
future would be beneficial to interrogate this interaction. 
Another plausible explanation for the marked similarity is that differences may lie 
within multigene families which were necessarily omitted in this analysis due to the poor 
current state of assembly of these largely repetitive sequences. It is likely that many of 
the virulence factors (such as trans-sialidases and MASPs) lie within these multigene 
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families. Using technologies that produce longer sequence reads will lead to a better 
assembly and annotation, which will resolve differences in multigene families and 
improve similar analyses in the future. There is work currently ongoing in other labs to 
finish the Sylvio genome into chromosomes using these technologies. 
The organs most affected in chronic Chagas disease are the heart and GI tract. 
This study uses human foreskin fibroblasts, not only to facilitate comparison with our 
previous work, but because these cells multiply in culture without being genetically 
modified. Fully differentiated non-cancer cardiomyocytes and GI smooth muscle cells do 
not multiply in culture, and are expensive to purchase and notoriously difficult to work 
with on the bench. Nevertheless, using more relevant cell lines might provide additional 
tissue-specific insights into the host-pathogen interaction of these parasite strains.  
Finally, differences at the proteome level may provide better insights into possible 
translational regulatory mechanisms not interrogated in this work. 
A unique benefit of using RNA-Seq in the context of this work is the ability to 
characterize the early behavior of both host and parasite simultaneously, even when 
parasite RNA levels are proportionally very small during the early timepoints of an 
infection. This study provides a unique look at the host-pathogen interaction between T. 
cruzi Sylvio strain and a human host, and the first in-depth comparative transcriptome 
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